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In 2014, the National Institute for Health Care 
Excellence (NICE) changed its guidelines 
for offering statins to patients, reducing the 
threshold from 20% cardiovascular risk to 
10%.1 This ignited a fervent debate about 
the wisdom and practicality of the change 
and raised three key questions: Do we really 
have the right evidence on which to make a 
decision about the risk/benefit balance? Is 
that evidence trustworthy when applied to 
patients seen in general practice? How can 
we communicate the best possible evidence 
to the people who need to make the relevant 
decisions: policy makers, clinicians, and the 
public? 
These questions are not, of course, specific 
to the issue of statins; they go to the heart 
of how healthcare decisions are made and 
as a result were the trigger for a request 
from the Chief Medical Officer of England to 
the Academy of Medical Sciences (AMS) to 
examine the issues in detail. The resulting 
report was finally published last month.2 The 
report presents 12 recommendations (Box 1) 
that are planned to address nothing less than 
the scientific basis of medicine: from deciding 
how research efforts should be targeted, to 
guidelines for science reporting in the media; 
from improving the methodology of clinical 
trials to the design of patient information 
leaflets. But what does it mean for GPs?
We believe that it raises a number of 
significant issues relating especially to 
shared decision making, the capacity and 
capabilities of health professionals and 
overmedicalisation.
SHARED DECISION MAKING
The theory of shared decision making is 
wonderfully simple: a healthcare professional 
will sit down with a patient and together they 
will discuss the potential benefits and risks 
of different treatment options, coming to a 
joint decision on the course of action that 
best suits the individual patient’s needs and 
priorities.
The report oversight group, however, 
in talking to GPs and the public, identified 
several familiar challenges in reaching this 
ideal. Time, trust, and understanding were 
all lacking, from the perspective of both 
clinicians and patients.
The report tackles the issues of trust with 
sections on the design, implementation, 
and interpretation of clinical research. That 
leaves the issues of communication of the 
resulting information, the skills to interpret it, 
and the time to do so. 
The report attempts to anticipate how 
patients might frame their questions, how 
clinicians might prepare for such questioning, 
and how both might be supported in terms 
of resources. Within primary care, NHS 
Choices and patient information leaflets were 
identified as key means to share trustworthy 
information on the potential risks and benefits 
of treatments and signpost resources that 
tend to be on disparate sites at present.
Much work has been done on how to 
get information across in ways that are 
clear and easily understood by a majority 
of people. One example mentioned in the 
report is the use of ‘facts boxes,’3 which 
summarise the key information that patients 
and healthcare professionals need to know, 
often using graphics alongside numbers to 
make comprehension easy at a glance. The 
report suggests that NHS Choices should 
consider including this sort of structured 
information on the potential benefits and 
harms of alternative options. Additionally, 
the report suggests that NHS Choices 
should provide tried-and-tested decision 
aids. These range from a simple set of 
suggested questions for a doctor to ask a 
patient (and vice versa) to online sites into 
which a patient’s personal information can 
be entered in order to produce individualised 
information and suggestions for the clinician 
and patient to discuss. Decision aids have 
been experimentally developed by both NICE4 
and NHS England,5 but the AMS report aims 
to put them firmly into the mainstream, 
suggesting that NICE coordinates their 
development, National Institute for Health 
Research and others fund their evaluation 
and assess their effectiveness, and that NHS 
Choices hosts them. 
The report also formulated a series of 
questions that patients and healthcare 
professionals are encouraged to consider 
in advance of every appointment, or to ask 
during it. The oversight group drew on 
many previous initiatives to add support and 
momentum to this movement, especially for 
patients who may not consider questioning 
their doctor.
THE CAPACITY AND CAPABILITIES OF 
HEALTH PROFESSIONALS
The idealised view of shared decision making 
is that in a comfortable consultation GPs will 
be able to present the evidence, discuss the 
pros and cons of any intervention and, with 
the patient’s involvement and agreement, 
proceed with an effective form of therapy 
or treatment to achieve the patient’s goals. 
There would be time for reflection and the 
patient would return to clarify any prevalent 
issues. The report’s oversight group 
recognised that none of this is easy to deliver 
in the current environment. 
Many GPs already use a variety of online 
resources to aid discussion of treatment 
options with patients,6 but having decision 
aids and other resources scattered over the 
internet makes it difficult to know the best 
place to turn. As mentioned, the report’s 
suggestion of adding clear information 
summaries to a trustworthy centralised 
resource (for example NHS Choices) where 
they can be kept up to date is, we hope, 
an ideal solution, if it can be funded and 
maintained to do this.
Until very recently, much medical 
training has (understandably, but perhaps 
problematically) concentrated on the theory 
and practice of medicine, and not covered the 
theory and practice of conducting research. 
Thus many, if not most, practising clinicians 
do not feel confident assessing the reliability 
of the methods and statistics employed in 
individual research papers, and even less so 
in communicating this evidence to patients.6
The report therefore calls for increased 
training at undergraduate and postgraduate 
levels in both the evaluation of scientific 
evidence and its communication, and 
encourages the Royal Colleges to provide 
continuing professional development 
(CPD) in both these areas for practising 
doctors. The RCGP already has a curriculum 
that includes the need to develop critical 
appraisal skills and its CPD programme 
complements the needs of speciality trainees 
to meet the requirements of the curriculum 
for the MRCGP examination. More on the 
communication of risk to patients may be 
called for, and the report recommends 
training in shared decision making and the 
use of decision aids as part of both medical 
school and CPD curricula for all clinicians.
REDUCING OVERMEDICALISATION, 
ESPECIALLY FOR PATIENTS WITH
MULTIMORBIDITY
Up to 44% of patients aged ≥75 years 
attending GP practices will have more 
than one medical condition.7 The RCGP 
has already raised concerns about the way 
that medicines are prescribed to this group 
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in particular8 and the report recognises 
that. Since patients with multimorbidity 
are usually excluded from clinical trials, 
there is doubt over the scientific basis for 
treatment decisions in their cases, along 
with the concern of potential unexpected 
drug interactions.9 
The report suggests that this gap in 
knowledge is addressed by clinical research; 
that planning is done to ensure that 
patients with multiple needs get the time 
they deserve; and that their treatment is 
focused on what really matters to them, 
encompassing lifestyle as well as medical 
interventions, and with a more personalised 
and self-managed approach in line with 
the recent NICE guidelines on dealing with 
multimorbidity.10 Decision aids, we believe, 
can help with these aims.
We recognise, though, that this approach 
will need GPs to spend adequate time 
with patients (often older patients) to go 
through their care options, understand their 
priorities and values, and discuss possible 
alternative options with them in a considered 
and appropriate way. Thus the report 
recommends that longer appointment times 
are prioritised for these patients in particular 
to establish a new system of care; clearly a 
challenge at the present time.
CONCLUSION
The 12 recommendations in the report 
are precise, with responsibilities and tasks 
assigned to particular institutions. Our hope 
is that this will encourage actual delivery 
of the resources and support that those 
working in primary care require in order 
to make the laudable ambitions of shared 
decision making a practical reality at last.
We know that doctors have always 
attempted to involve their patients in 
decisions where there is a genuine choice 
to be made, to keep abreast of the latest 
evidence on effectiveness, and to care 
for their patients with multimorbidity in a 
personalised way. Equally, we recognise 
that the ambitions of health professionals in 
primary care will continue to be constrained 
by workforce pressures, patient demand, 
and the increased management required 
around polypharmacy and multimorbidity, 
unless significant cultural and structural 
changes are made. We hope that this report 
stimulates exactly those sorts of changes.
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Box 1: The 12 
recommendations
Ensuring evidence is robust and relevant:
1. Patients, carers and the public should be  
 more involved in the direction, delivery and  
 dissemination of clinical research.
2. All those involved in clinical research and  
 all healthcare professionals (at all career  
 stages) should get a grounding in the  
 research methods and statistics used to  
 evaluate the benefits and harms of treatment  
 options.
3. The importance of robust, reproducible and  
 reliable research should be recognised and  
 emphasised.
4. That new sources of evidence should be  
 used to best advantage, with more emphasis  
 on finding ways to extract and share useful  
 data from every opportunity.
Ensuring evidence is trustworthy:
5. That research findings and data should be  
 published in as open, balanced and full way  
 as possible.
6. That any potential conflicts of interest are  
 routinely declared and then managed in an  
 open and transparent way.
7. That academia-industry relationships are  
 managed under a set of clear guidelines.
Ensuring evidence is communicated and 
used effectively:
8. That patient information leaflets are improved  
 to give a clear and balanced appraisal of the  
 potential risks and benefits of treatment  
 options.
9. That NHS Choices becomes a central  
 repository of clear, balanced and up to date  
 evidence on healthcare options.
10. That improved reporting of scientific evidence  
 in the media is encouraged, with a role for  
 academic establishments in ensuring their  
 research is accurately reflected.
11. Increased support for shared decision- 
 making, including adequate resourcing of  
 primary care services and the provision of  
 decision aids through NHS Choices.
12. Continued dialogue and engagement with  
 patients and the public to monitor the  
 impact of these recommendations and  
 ensure responsiveness to changing public  
 needs in health care.
